{"success":true,"data":{"pressRelease":{"id":"46956","rtpr_id":"nBw3sZtjba","ticker":"ZTS","exchange":"NYSE","all_tickers":["ZTS"],"title":"Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives","author":"Business Wire","published_at":"2026-05-27T19:08:00.090Z","article_body":"Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc.\nand Certain of Its Executives\n\nLabaton Keller Sucharow LLP (“Labaton”) has filed a securities class\naction lawsuit (the “Action”) on behalf of its client the City of Ann\nArbor Retiree Health Care Benefit Plan & Trust (“Ann Arbor RHC”)\nagainst Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) and\ncertain of its executives (collectively, “Defendants”). The Action, which\nis captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v.\nZoetis, Inc., No. 26-cv-04401 (S.D.N.Y.), asserts claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and\nExchange Commission Rule 10b-5 promulgated thereunder on behalf of all persons\nand entities that purchased or otherwise acquired Zoetis securities between\nJanuary 14, 2025 and May 6, 2026, inclusive (the “Class Period”).\n\nZoetis is an animal health company that develops, manufactures, and sells\nvaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions\nfor companion animals and livestock. Zoetis’ Companion Animal products for\ndogs and cats are its most important line of business and its principal growth\nengine.\n\nThe Action alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements concerning the growth, competitive\npositioning, market share, and veterinarian adoption of key products within\nthe Companion Animal segment while failing to disclose that: (i) veterinarian\nprescription growth and adoption of Zoetis’ Librela, a canine pain\ntreatment, were sharply weakening as clinicians became more cautious following\nFDA safety warnings concerning serious neurological complications in dogs;\n(ii) Zoetis’ Simparica Trio was losing significant market share to a lower\npriced competing canine parasiticide with broader indicated use in a slowing\noverall market; and (iii) Zoetis’ dermatology products, Apoquel and\nCytopoint, were losing substantial market share to a newly launched competing\ncanine treatment.\n\nThe market began to learn the truth about Defendants’ fraud through a series\nof disclosures beginning in August 2025 that revealed weakening demand trends,\nslowing veterinarian adoption, intensifying competitive pressures, and\ndeclining growth across Zoetis’ key Companion Animal franchises. Over the\nfollowing months, additional disclosures further revealed the extent of the\ndeterioration affecting the Company’s core growth products, culminating on\nMay 7, 2026, when Zoetis reported first quarter 2026 financial results\nreflecting significant deterioration across its Companion Animal business and\nsharply reduced its full year guidance. On this news, Zoetis stock price\ndropped 21.5 percent, closing at $87.31 per share on May 7, 2026.\n\nIf you purchased or acquired Zoetis securities during the Class Period and\nwere damaged thereby, you are a member of the “Class” and may be able to\nseek appointment as Lead Plaintiff. Lead Plaintiff motion papers must be filed\nno later than July 27, 2026. The Lead Plaintiff is a court-appointed\nrepresentative for absent members of the Class. You do not need to seek\nappointment as Lead Plaintiff to share in any Class recovery in this action.\nIf you are a Class member and there is a recovery for the Class, you can share\nin that recovery as an absent Class member. You may retain counsel of your\nchoice to represent you in this action.\n\nIf you would like to consider serving as Lead Plaintiff or have any questions\nabout this lawsuit, you may contact Connor C. Boehme, Esq. of Labaton at +1\n(212) 907-0780, or via email at cboehme@labaton.com\n(mailto:cboehme@labaton.com) . You can view a copy of the Complaint online\nhere\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.labaton.com%2Fnews-insights%2Flabaton-keller-sucharow-llp-files-securities-class-action-against-zoetis-and-certain-of-its-executives&esheet=54542903&newsitemid=20260527123189&lan=en-US&anchor=here&index=9&md5=26a3625e0798b68ac1e3fd7cf9e52f47)\n.\n\nAnn Arbor RHC is represented by Labaton, which represents many of the largest\npension funds in the United States and internationally with combined assets\nunder management of more than $6 trillion. Labaton’s litigation reputation\nis built on its half-century of securities litigation experience, more than\nninety full-time attorneys, and in-house team of investigators, financial\nanalysts, and forensic accountants. Labaton has been recognized for its\nexcellence by the courts and peers, and it is consistently ranked in leading\nindustry publications. Offices are located in New York, Delaware, London, and\nWashington, D.C. More information about Labaton is available at labaton.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.labaton.com%2F&esheet=54542903&newsitemid=20260527123189&lan=en-US&anchor=labaton.com&index=10&md5=0c0e3fcf724c83eaf93b253eb33cd1b8)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527123189/en/\n(https://www.businesswire.com/news/home/20260527123189/en/)\n\nConnor C. Boehme, Esq.\nLabaton Keller Sucharow LLP\n+1 (212) 907-0780\ncboehme@labaton.com (mailto:cboehme@labaton.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3sZtjba","title":"Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives","author":"Business Wire","ticker":"ZTS","created":"2026-05-27T19:08:00.090Z","tickers":["ZTS"],"exchange":"NYSE","article_body":"Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc.\nand Certain of Its Executives\n\nLabaton Keller Sucharow LLP (“Labaton”) has filed a securities class\naction lawsuit (the “Action”) on behalf of its client the City of Ann\nArbor Retiree Health Care Benefit Plan & Trust (“Ann Arbor RHC”)\nagainst Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) and\ncertain of its executives (collectively, “Defendants”). The Action, which\nis captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v.\nZoetis, Inc., No. 26-cv-04401 (S.D.N.Y.), asserts claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and\nExchange Commission Rule 10b-5 promulgated thereunder on behalf of all persons\nand entities that purchased or otherwise acquired Zoetis securities between\nJanuary 14, 2025 and May 6, 2026, inclusive (the “Class Period”).\n\nZoetis is an animal health company that develops, manufactures, and sells\nvaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions\nfor companion animals and livestock. Zoetis’ Companion Animal products for\ndogs and cats are its most important line of business and its principal growth\nengine.\n\nThe Action alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements concerning the growth, competitive\npositioning, market share, and veterinarian adoption of key products within\nthe Companion Animal segment while failing to disclose that: (i) veterinarian\nprescription growth and adoption of Zoetis’ Librela, a canine pain\ntreatment, were sharply weakening as clinicians became more cautious following\nFDA safety warnings concerning serious neurological complications in dogs;\n(ii) Zoetis’ Simparica Trio was losing significant market share to a lower\npriced competing canine parasiticide with broader indicated use in a slowing\noverall market; and (iii) Zoetis’ dermatology products, Apoquel and\nCytopoint, were losing substantial market share to a newly launched competing\ncanine treatment.\n\nThe market began to learn the truth about Defendants’ fraud through a series\nof disclosures beginning in August 2025 that revealed weakening demand trends,\nslowing veterinarian adoption, intensifying competitive pressures, and\ndeclining growth across Zoetis’ key Companion Animal franchises. Over the\nfollowing months, additional disclosures further revealed the extent of the\ndeterioration affecting the Company’s core growth products, culminating on\nMay 7, 2026, when Zoetis reported first quarter 2026 financial results\nreflecting significant deterioration across its Companion Animal business and\nsharply reduced its full year guidance. On this news, Zoetis stock price\ndropped 21.5 percent, closing at $87.31 per share on May 7, 2026.\n\nIf you purchased or acquired Zoetis securities during the Class Period and\nwere damaged thereby, you are a member of the “Class” and may be able to\nseek appointment as Lead Plaintiff. Lead Plaintiff motion papers must be filed\nno later than July 27, 2026. The Lead Plaintiff is a court-appointed\nrepresentative for absent members of the Class. You do not need to seek\nappointment as Lead Plaintiff to share in any Class recovery in this action.\nIf you are a Class member and there is a recovery for the Class, you can share\nin that recovery as an absent Class member. You may retain counsel of your\nchoice to represent you in this action.\n\nIf you would like to consider serving as Lead Plaintiff or have any questions\nabout this lawsuit, you may contact Connor C. Boehme, Esq. of Labaton at +1\n(212) 907-0780, or via email at cboehme@labaton.com\n(mailto:cboehme@labaton.com) . You can view a copy of the Complaint online\nhere\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.labaton.com%2Fnews-insights%2Flabaton-keller-sucharow-llp-files-securities-class-action-against-zoetis-and-certain-of-its-executives&esheet=54542903&newsitemid=20260527123189&lan=en-US&anchor=here&index=9&md5=26a3625e0798b68ac1e3fd7cf9e52f47)\n.\n\nAnn Arbor RHC is represented by Labaton, which represents many of the largest\npension funds in the United States and internationally with combined assets\nunder management of more than $6 trillion. Labaton’s litigation reputation\nis built on its half-century of securities litigation experience, more than\nninety full-time attorneys, and in-house team of investigators, financial\nanalysts, and forensic accountants. Labaton has been recognized for its\nexcellence by the courts and peers, and it is consistently ranked in leading\nindustry publications. Offices are located in New York, Delaware, London, and\nWashington, D.C. More information about Labaton is available at labaton.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.labaton.com%2F&esheet=54542903&newsitemid=20260527123189&lan=en-US&anchor=labaton.com&index=10&md5=0c0e3fcf724c83eaf93b253eb33cd1b8)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527123189/en/\n(https://www.businesswire.com/news/home/20260527123189/en/)\n\nConnor C. Boehme, Esq.\nLabaton Keller Sucharow LLP\n+1 (212) 907-0780\ncboehme@labaton.com (mailto:cboehme@labaton.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-27T19:08:00.133373865Z","server_sent_at_ms":1779908880133},"received_at":"2026-05-27T19:08:00.200Z","source_url":"https://www.businesswire.com/news/home/20260527123189/en/"},"analysis":{"id":"36389","press_release_id":"46956","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Labaton Keller Sucharow LLP filed a securities class action against Zoetis and certain executives on behalf of the City of Ann Arbor Retiree Health Care Benefit Plan.\n\nThe complaint alleges materially false statements regarding the growth and competitive positioning of key Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint, during the class period of January 14, 2025 to May 6, 2026.\n\nThe release serves as a solicitation for investors to contact the firm regarding lead plaintiff appointment, with a deadline of July 27, 2026. It is a law-firm marketing notice, not an issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"stock_drop_pct":"21.5%","class_period_end":"May 6, 2026","class_period_start":"January 14, 2025","closing_price_on_drop":"$87.31","lead_plaintiff_deadline":"July 27, 2026"}},"quotedText":"If you would like to consider serving as Lead Plaintiff or have any questions about this lawsuit, you may contact Connor C. Boehme, Esq. of Labaton","namedEntities":{"people":[{"name":"Connor C. Boehme","role":"Attorney at Labaton Keller Sucharow LLP"}],"products":["Librela","Simparica Trio","Apoquel","Cytopoint"],"companies":[{"name":"Labaton Keller Sucharow LLP","relationship":"plaintiff law firm"},{"name":"Zoetis, Inc.","ticker":"ZTS","relationship":"defendant"},{"name":"City of Ann Arbor Retiree Health Care Benefit Plan & Trust","relationship":"plaintiff client"}],"dollarAmounts":[{"amount":"$87.31","context":"closing stock price on May 7, 2026"},{"amount":"$6 trillion","context":"combined assets under management of Labaton's clients"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by Labaton Keller Sucharow LLP. It is a routine class-action filing notice and lead-plaintiff deadline reminder, not an issuer disclosure. Per guardrails, such releases are scored as low-impact noise (score 1) with neutral sentiment."},"tickerRelevance":{"others":[],"primary":"ZTS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"householdBrandBoost":5}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Labaton Keller Sucharow LLP filed a securities class action against Zoetis and certain executives on behalf of the City of Ann Arbor Retiree Health Care Benefit Plan.\n\nThe complaint alleges materially false statements regarding the growth and competitive positioning of key Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint, during the class period of January 14, 2025 to May 6, 2026.\n\nThe release serves as a solicitation for investors to contact the firm regarding lead plaintiff appointment, with a deadline of July 27, 2026. It is a law-firm marketing notice, not an issuer disclosure.","key_figures":{"customDimensions":{"stock_drop_pct":"21.5%","class_period_end":"May 6, 2026","class_period_start":"January 14, 2025","closing_price_on_drop":"$87.31","lead_plaintiff_deadline":"July 27, 2026"}},"named_entities":{"people":[{"name":"Connor C. Boehme","role":"Attorney at Labaton Keller Sucharow LLP"}],"products":["Librela","Simparica Trio","Apoquel","Cytopoint"],"companies":[{"name":"Labaton Keller Sucharow LLP","relationship":"plaintiff law firm"},{"name":"Zoetis, Inc.","ticker":"ZTS","relationship":"defendant"},{"name":"City of Ann Arbor Retiree Health Care Benefit Plan & Trust","relationship":"plaintiff client"}],"dollarAmounts":[{"amount":"$87.31","context":"closing stock price on May 7, 2026"},{"amount":"$6 trillion","context":"combined assets under management of Labaton's clients"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-27T19:08:13.389Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"householdBrandBoost":5}},"durationMs":13167,"modelName":"george-droid-qwen-72b"}}